Skip to main content
Clinical Trials/NCT04071730
NCT04071730
Completed
Not Applicable

Effects of Immulina Dietary Supplementation on Innate and Adaptive Immune Measures in Normal Human Volunteers

University of Mississippi Medical Center1 site in 1 country40 target enrollmentSeptember 3, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Effects of Immulina on Natural Killer Cells
Sponsor
University of Mississippi Medical Center
Enrollment
40
Locations
1
Primary Endpoint
Natural Killer (NK) cell count
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

This small, randomized, double blind, placebo controlled pilot study is aimed at determining the effects of oral Immulina dietary supplementation on specific immune biomarkers in the blood.

Detailed Description

This small, randomized, double blind, placebo controlled pilot study is aimed at determining the effects of four weeks of daily Immulina dietary supplementation (800 mg/day) versus four weeks of daily placebo on natural killer (NK) cell numbers and/or natural killer (NK) cell activity in human peripheral blood mononuclear cells collected from human research participants who meet the trial's inclusion/exclusion criteria.

Registry
clinicaltrials.gov
Start Date
September 3, 2019
End Date
March 11, 2021
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Gailen D. Marshall Jr., MD PhD

The R. Faser Triplett, Sr., MD Chair of Allergy and Immunology, Professor of Medicine, Pediatrics, Pathology and Population Science

University of Mississippi Medical Center

Eligibility Criteria

Inclusion Criteria

  • Normal, generally healthy adults between ages 18-64 and who may or may not have a controlled disease(s). Examples of controlled diseases are controlled Type-2 diabetes mellitus, controlled hypertension, controlled allergic rhinitis, etc.

Exclusion Criteria

  • Individuals with specific disease entities, which, in the opinion of the Principal Investigator, could reasonably be assumed to have dysfunctional immune function as a component of their illness. These include HIV, AIDS, uncontrolled asthma, uncontrolled eczema, uncontrolled allergic rhinitis, uncontrolled urticaria, rheumatoid arthritis, lupus, inflammatory bowel disease, multiple sclerosis, Type-1 diabetes mellitus, Guillain-Barre syndrome, psoriasis, Grave's disease, Hashimoto's thyroiditis, myasthenia gravis or vasculitis.
  • Individuals taking specific dietary supplements including probiotic, microalgae or beta glucan containing dietary supplements, fermented food products (such as yogurt, bean curd, etc.). If the potential participants reports usage of any of these products, they will be asked if they would be willing to withhold products for 30 days and then be re-screened for inclusion/exclusion criteria.
  • Individuals who are unwilling to refrain for the duration of the trial from taking the specific dietary supplements and fermented food products including probiotic, microalgae or beta glucan containing dietary supplements, fermented food products (such as yogurt, bean curd, etc.).
  • Pregnant females (because baseline immune responses, are altered by pregnancy)
  • Individuals unable to speak, understand and read English

Outcomes

Primary Outcomes

Natural Killer (NK) cell count

Time Frame: 4 weeks

Differences in NK cell counts from baseline to 4 weeks

Secondary Outcomes

  • Natural Killer (NK) cell cytotoxic activity(4 weeks)
  • Immune cell populations(4 weeks)
  • Cytokine profiles(4 weeks)

Study Sites (1)

Loading locations...

Similar Trials